Evopoint Biosciences Inc.
Clinical trials sponsored by Evopoint Biosciences Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced cancers: experimental drug XNW28012 enters human trials Results expected Dec 2026 (estimated)
- New drug candidate takes aim at Hard-to-Treat pancreatic cancer Results expected May 2027 (estimated)
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called XNW5004 in 120 people with advanced tumors or lymphoma that had come back or stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see if it helps shrink tumors. The drug is taken as a tabl…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New antibiotic cocktail aims to beat tough hospital pneumonia
Disease control CompletedThis study tested a new antibiotic combination (IMI-XNW4107) against an existing one (IMI/REL) in 450 adults with serious pneumonia caught in the hospital or from a ventilator. The main goal was to see if the new drug was at least as good at preventing death within 14 days. Both …
Phase 3 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC